Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-120 Nasal Spray for SARS-CoV-2 Post Exposure Prophylaxis
NCT05765279Completed
- Sponsor
- Beijing Ditan Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, single-blind trial of HH-120 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Proportion of subjects who have a RT-qPCR confirmed SARS-CoV-2 infection. Started Oct 2022; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05765279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765279.